According to Mayo Clinic researchers, the HbA1c level targeted by physicians may not actually lower the risk of kidney, vision and neuropathy complications for diabetics, contrary to longstanding belief.
The glucocentric focus on lowering blood sugar in Type 2 diabetes may have short-circuited development of new diabetes therapies, according to a new paper published by Mayo Clinic researchers in the journal Circulation: Cardiovascular Quality and Outcomes.
The authors, Victor Montori, M.D., and Rene Rodriguez-Gutierrez, M.D., of the Knowledge and Evaluation Research Unit at Mayo Clinic, systematically examined journal articles and clinical practice diabetes guidelines published in the last decade (2006 and 2015) for statements related to value of tight glycemic control in the prevention of chronic diabetic complications.
The authors then compared them with the body of evidence accrued in the past two decades regarding the effect of tight glycemic control on patient-important micro- and macrovascular outcomes.
The study, funded by Mayo Clinic’s Clinical and Translational Science Award, found that tight glycemic control (maintenance of a hemoglobin A1c value, or HbA1c, lower than 7 percent) had no statistically significant impact on patient-important microvascular outcomes (end-stage renal disease/dialysis, renal death, blindness and clinical neuropathy).
In contrast, all practice guidelines and a majority of published statements (around 80 percent) support tight glycemic control to prevent those complications.
For patient-important macrovascular (cardiovascular) complications, the evidence shows that tight glycemic control reduces the risk of nonfatal heart attack by around 15 percent, but has no impact in all-cause mortality and cardiovascular mortality.
Also, the risk of stroke did not seem to be lowered by tight glycemic control and the effect on amputation was imprecise.
During the studied time period, statements about tight glycemic control to prevent these complications shifted from largely supportive (85 percent) to skeptical (20-30 percent) after the publication of a single study (the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial) in 2008 that is not consistent with the results of other studies (body of evidence).
This News Story Continues Below
Overall, the authors suggest that the widespread consensus for tight glycemic control should be re-examined.
Drs. Rodriguez-Gutierrez and Montori write that they hope this paper will spur research into new therapeutic approaches to prevent diabetes complications. They write, “Consider the list of evidence-based therapies recommended… to prevent retinopathy or neuropathy beyond glycemic control: none.”
Instead of focusing on tight glycemic control, the authors suggest glycemic moderation may help advance the individualization of diabetes care, using shared decision making to select glycemic targets and treatments.
The authors point out that patients with Type 2 diabetes seem to live longer and with fewer complications, at least in some parts of the world, and suggest a careful and thoughtful recalibration of treatment could promote patient trust and provide new answers to this pandemic problem.
The publication of this paper was supported by Mayo Clinic’s Center for Clinical and Translational Science through a Clinical and Translational Science Award from the National Center for Advancing Translational Sciences, a component of the National Institutes of Health.
What do you think about this story?
Share your thoughts, or see what other readers had to say, in the comments section (just scroll below).